<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966901</url>
  </required_header>
  <id_info>
    <org_study_id>A6431087</org_study_id>
    <secondary_id>009/05-03.NPT</secondary_id>
    <secondary_id>2005-001641-41</secondary_id>
    <nct_id>NCT00966901</nct_id>
  </id_info>
  <brief_title>Photoirritation and Photoallergic Potential of a New Nicotine Patch</brief_title>
  <official_title>Assessment of Photoirritation and Photoallergic Potential of a Newly Developed Nicotine Transdermal Therapeutic System (TTS) After Single and Multiple Application and Multiple UV Exposure in Healthy Subjects. A Standard Photocontact Allergenicity Assay.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An evaluation of the effects of UV exposure following the use of a new nicotine patch.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An evaluation on the phototoxic potential of a newly developed nicotine patch after a single&#xD;
      dose application followed by UV exposure, and an evaluation on the photoallergenic potential&#xD;
      of the new nicotine patch after multiple dose applications followed by UV exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Individual Irritation Scores after UVA and UVB exposure</measure>
    <time_frame>15 or 30 min, and 24, 48, and 72 hr post-application, depending on trial phase.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Irritation Score (IIS)</measure>
    <time_frame>15 min post-application, and 30 min, 24 h, 48 h, and 72 h after irradiation, depending on trial phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patch adhesion score</measure>
    <time_frame>directly before patch removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Three Treatment Sites UV Exposed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.</description>
    <arm_group_label>Three Treatment Sites UV Exposed</arm_group_label>
    <other_name>Experimental Nicotine Patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.</description>
    <arm_group_label>Three Treatment Sites UV Exposed</arm_group_label>
    <other_name>Positive Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Patch Control</intervention_name>
    <description>As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.</description>
    <arm_group_label>Three Treatment Sites UV Exposed</arm_group_label>
    <other_name>Negative Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>UVA and UVB irradiation</intervention_name>
    <description>All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)</description>
    <arm_group_label>Three Treatment Sites UV Exposed</arm_group_label>
    <other_name>Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females between 18 and 65 years.&#xD;
&#xD;
          -  Heavy smokers (more than 10 cigarettes per day) and willing to reduce the number of&#xD;
             cigarettes smoked during the course of the study.&#xD;
&#xD;
          -  Having had no febrile or infectious illness for at least seven days prior to the first&#xD;
             administration of the investigational product.&#xD;
&#xD;
          -  Women practicing one or a combination of the following methods of birth control:&#xD;
             hormonal contraceptives, condoms, sponge, foams, jelly, diaphragm, or intrauterine&#xD;
             device, or women who are surgically sterilized.&#xD;
&#xD;
          -  Subjects having normal skin without excessive hair growth on tested areas and baseline&#xD;
             score in skin reaction assessment of &quot;0&quot; on tested areas.&#xD;
&#xD;
          -  Skin type I, II, or III according to Fitzpatrick.&#xD;
&#xD;
          -  Evaluable MED (the lowest dose to produce mild erythema with visible borders) to UVB.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subjects have been informed of all pertinent aspects of the trial.&#xD;
&#xD;
          -  Subjects who are willing to comply with scheduled visits, treatment plan and other&#xD;
             trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any visible skin disorder, abnormal skin pigmentation, fissure or injury of the skin,&#xD;
             which, in the opinion of the investigator, would interfere with the results of the&#xD;
             trial.&#xD;
&#xD;
          -  History of dermatological disease or medical conditions (in particular, any&#xD;
             immunosuppression) which could, in the opinion of the investigator, preclude topical&#xD;
             application of the investigational products and/or interfere with the evaluation of&#xD;
             the test site reaction.&#xD;
&#xD;
          -  History of clinically relevant psoriasis, chronic dermatitis or urticaria.&#xD;
&#xD;
          -  Clinically relevant abnormal findings from the physical examination.&#xD;
&#xD;
          -  Pregnant (verified by beta-HCG-test in urine) and/or nursing women.&#xD;
&#xD;
          -  Any suspicion or evidence of current alcohol or drug abuse or history of alcohol or&#xD;
             drug abuse within the last three years.&#xD;
&#xD;
          -  Any current or past history of chronic or recurrent metabolic, renal, hepatic,&#xD;
             pulmonary, gastrointestinal, neurological, endocrinological (including&#xD;
             pheochromocytoma), immunological, psychiatric or cardiovascular disease, myopathies,&#xD;
             epileptic seizures and bleeding tendency.&#xD;
&#xD;
          -  Recent myocardial infarct (within last 3 months), unstable or deteriorating angina&#xD;
             pectoris, coronary artery vasospasm (Prinzmetal's angina), serious cardiac&#xD;
             arrhythmias, and acute stroke.&#xD;
&#xD;
          -  History of myopathies or epileptic seizures.&#xD;
&#xD;
          -  Use of any medication within four weeks prior to the first treatment or during the&#xD;
             trial, which, in the opinion of the investigator, may influence the trial results or&#xD;
             the safety of the subjects.&#xD;
&#xD;
          -  Use of systemic or topical analgesics or antihistamines within 72 hours prior to trial&#xD;
             enrollment (except paracetamol) or systemic or topical corticosteroids within three&#xD;
             weeks of trial enrollment.&#xD;
&#xD;
          -  Subjects having used nicotine products other than cigarettes within the three months&#xD;
             preceding the trial.&#xD;
&#xD;
          -  Participation in the treatment phase of a clinical trial within 30 days prior to the&#xD;
             treatment phase of this trial, or within 10 times the respective elimination half-life&#xD;
             of the investigational drug.&#xD;
&#xD;
          -  Subjects who cannot avoid, throughout the duration of the trial, any swimming, any&#xD;
             washing of the lower back (i.e., the areas which to be patched and/or irradiated&#xD;
             during this study), usage of sauna or any intense physical activity that might result&#xD;
             in excessive sweating.&#xD;
&#xD;
          -  Any history of drug hypersensitivity, asthma, urticaria, or other severe allergic&#xD;
             diathesis as well as current hay fever.&#xD;
&#xD;
          -  Known sensitivity to adhesive tape.&#xD;
&#xD;
          -  Known sensitivity to any component of the test products.&#xD;
&#xD;
          -  History of irritation to topically applied products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IKP GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

